Weekly Analysts’ Ratings Changes for Medtronic (MDT)

Medtronic (NYSE: MDT) has recently received a number of price target changes and ratings updates:

• 4/23/2026 – Medtronic had its “hold” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $95.00 price target on the stock.
• 4/22/2026 – Medtronic had its price target lowered by UBS Group AG from $104.00 to $90.00. They now have a “neutral” rating on the stock.
• 4/21/2026 – Medtronic was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
• 4/15/2026 – Medtronic had its price target lowered by Truist Financial Corporation from $103.00 to $95.00. They now have a “hold” rating on the stock.
• 4/15/2026 – Medtronic had its price target raised by Robert W. Baird from $92.00 to $93.00. They now have a “neutral” rating on the stock.
• 4/13/2026 – Medtronic had its price target lowered by Mizuho from $125.00 to $120.00. They now have an “outperform” rating on the stock.
• 4/11/2026 – Medtronic was downgraded by Wall Street Zen from “buy” to “hold”.
• 4/9/2026 – Medtronic was given a new $106.00 price target by Evercore Inc. They now have an “outperform” rating on the stock.
• 4/7/2026 – Medtronic had its price target lowered by Citigroup Inc. from $117.00 to $110.00. They now have a “buy” rating on the stock.
• 4/6/2026 – Medtronic had its price target lowered by Evercore Inc from $115.00 to $108.00. They now have an “outperform” rating on the stock.
• 4/6/2026 – Medtronic had its price target lowered by Stifel Nicolaus from $105.00 to $95.00. They now have a “hold” rating on the stock.
• 4/6/2026 – Medtronic had its price target lowered by Argus from $125.00 to $115.00. They now have a “buy” rating on the stock.
• 4/1/2026 – Medtronic had its price target raised by Barclays PLC from $118.00 to $120.00. They now have an “overweight” rating on the stock.
• 4/1/2026 – Medtronic had its price target lowered by Piper Sandler from $105.00 to $91.00. They now have a “neutral” rating on the stock.
• 3/28/2026 – Medtronic was upgraded by Wall Street Zen from “hold” to “buy”.
• 3/26/2026 – Medtronic had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $120.00 price target on the stock.
• 3/10/2026 – Medtronic had its “outperform” rating reaffirmed by Leerink Partners. They now have a $119.00 price target on the stock.
• 3/10/2026 – Medtronic had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $120.00 price target on the stock.
• 3/1/2026 – Medtronic was downgraded by Wall Street Zen from “buy” to “hold”.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, April 17th. Stockholders of record on Friday, March 27th were issued a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.5%. The ex-dividend date of this dividend was Friday, March 27th. Medtronic’s dividend payout ratio (DPR) is presently 79.11%.

Insider Activity

In other news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This trade represents a 61.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.26% of the stock is currently owned by insiders.

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).